TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06287918: A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 130 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06287918 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06287918 Rescue Dossier →